The vaccine given to children to immunize against serious pneumococcal disease does not offer full protection, reveals research from the Sahlgrenska Academy at the University of Gothenburg, Sweden, finding that the number of cases diagnosed has tripled over the past 50 years.
Each year an estimated 1 million children worldwide die as a result of pneumococcal disease. Worst affected are those in poor countries, but pneumococcal bacteria cause disease and suffering in all age groups and in all countries, including Sweden.
There are currently two types of active vaccine: polysaccharide vaccines, which protect against more types of pneumococcal bacteria but cannot be given to children under the age of two, and conjugated vaccines, which can be given to infants but protect against fewer types.
Â
In his thesis, Erik Backhaus, infection specialist at Skövde Hospital and doctoral student at the University of Gothenburg's Sahlgrenska Academy, looks at all cases of serious pneumococcal disease in children and adults in the Västra Götaland region of Sweden between 1998 and 2001. His studies show that the latest conjugated vaccines theoretically offer protection against around 70 percent of infections. "But around 95 percent of infections are caused by serotypes covered by the polysaccharide vaccine," says Backhaus. "This vaccine cannot be administered to children under two years of age, which means that it cannot be used in those who need it most."
In the worst case, the bacteria cause serious disease from which around 10 percent of patients die within a month of diagnosis. Erik Backhaus shows in his thesis that the risk of dying depends partly on age and partly on underlying medical conditions, but also that the risk is higher for men than women. Interestingly there are also geographical variations: fewer serious pneumococcal infections are diagnosed in the over-80s in the Gothenburg area than in other parts of the Västra Götaland region.
Â
"This may be due to different routines for admitting patients from nursing homes to hospital and how often blood cultures are performed," he explains.
Over the past 45 years the number of cases of severe pneumococcal disease diagnosed in the Gothenburg area has tripled from 5 to 15 cases per 100,000 inhabitants per year. This is probably because many more blood cultures are performed these days, meaning that more cases are detected. Erik Backhaus' thesis shows that the risk of dying as a result of serious pneumococcal disease has fallen sharply since the 1960s, especially among children and young adults.
It is hoped that the recently introduced pneumococcal vaccination as part of the standard child immunization program will reduce the number of infections among both children and adults.
The thesis "Invasive Pneumococcal Infections" was successfully defended at the Sahlgrenska Academy's Institute of Biomedicine on Jan. 13, 2012.
Pneumococcal bacteria belong to the Streptococcus genus and are the most common cause of bacterial respiratory infections. There are 90 different types of pneumococcal bacteria, of which ten are dominant in small children. The diseases caused range from uncomplicated upper respiratory tract infections through pneumonia of varying severity to serious and sometimes life-threatening conditions such as meningitis and septicaemia. The risk of disease is highest among the very young, the very old and those suffering from various chronic diseases
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.